|
Medication
|
Subjects
| | | |
|---|
| |
#1 (wt/wt)
|
#2 (wt/wt)
|
#3 (wt/*2)
|
#4 (wt/*2)
|
|
baseline
|
normal
|
normal
|
normal
|
normal
|
|
(day 0)
|
85 U
|
79 U
|
89 U
|
101 U
|
|
clopidogrel mono-therapy
|
inhibited
|
inhibited
|
normal
|
inhibited
|
|
(day 7)
|
42 U
|
16 U
|
97 U
|
31 U
|
|
clopidogrel and omeprazole
|
inhibited
|
inhibited
|
n.s.*
|
normal
|
|
taken together (day 14)
|
44 U
|
10 U
| |
74 U
|
|
clopidogrel and omeprazole
|
n.s.*
|
n.s.*
|
n.s*
|
normal
|
|
intake separated (day 21)
| | | |
67 U
|
|
clopidogrel and rabeprazole
|
n.s.*
|
n.s.*
|
n.s.*
|
inhibited
|
|
taken together (day 28)
| | | |
43 U
|
- The reference range of the test was 53-122 U.
- Clopidogrel intake inhibits ADP-induced platelet aggregation in subjects showing the expected clopidogrel effect. Normal platelet function under clopidogrel mono-therapy represents a non-responder status. The normalization of platelet function by co-therapy with clopidogrel and PPI after platelet function is inhibited by clopidogrel mono-therapy indicates a pharmacologically relevant drug interaction.
- *n.s., not studied, according to protocol.
